Abivax S.A.

NASDAQ:ABVX

Biotechnology

Healthcare
$83.83 -0.61%

-$0.62 today

Market cap
$7.34B
Beta
-0.20
P/E (TTM)
-18.1
EPS (TTM)
-$4.83
52W Low $5.69High $148.83

Volume 1.19M

Average 1.59M

ABVX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Abivax S.A.NASDAQ: ABVX

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation grows 165.3% year over year

Q2 FY2026 stock-based compensation of €16.8M rose 165.3% year over year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
€16.8M— QoQ
Last fiscal yearDec 2025
€0-100.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+165.3%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

EUR · from the cash flow

Latest · FY2025
0 EUR
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How ABVX compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -100.0% is the lowest of 11, against a peer median of +9.6%.
ABVX Competitors
Stock-Based Compensation for ABVX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$63M USD-6.0%-2.6%53.8%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$50.3M USD+35.9%+74.2%55.6%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$49.18M USD+10.5%+43.7%22.6%
ANABAnaptysBio, Inc.LTM Mar 2026$41.12M USD+24.3%+9.7%17.7%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$40.66M USD+8.7%+10.5%5.8%
IVAInventiva S.A.FY2025€26.77M EUR+647.7%+129.4%597.1%
ANNXAnnexon, Inc.LTM Mar 2026$15.5M USD-21.9%-3.9%—
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$13.96M USD+64.9%+21.7%23652.5%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$12.05M USD-2.1%-6.3%144.0%
IMMXImmix Biopharma, Inc.LTM Mar 2026$2.15M USD-27.0%+57.6%—
ABVXAbivax S.A.FY2025€0 EUR-100.0%——
Peer median (excluding ABVX) —+9.6%+16.1%54.7%

Competitors are the stored peer set for ABVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(42.45M)(60.74M)(147.74M)(176.24M)(322.84M)
Depreciation & Amortization302K485K707K1.1M1.07M
Deferred Income Tax007.93M00
Stock-Based Compensation828K(1.16M)8.18M20.22M0
Change in Working Capital(668K)(2M)21.27M1.42M3.51M
Accounts Receivables(1.98M)312K(14.23M)4.59M6.76M
Inventory00000
Accounts Payables1.14M(2.39M)31.76M(3.44M)0
Other Working Capital168K74K3.74M276K(3.26M)
Other Non-Cash Items(3.06M)9.49M9.65M(577K)162.57M
Operating Cash Flow(45.05M)(53.94M)(100.01M)(154.07M)(155.69M)
Capital Expenditures(47K)(323K)(265K)(643K)(136.4K)
Acquisitions (Net)(2.18M)(2.91M)000
Purchases of Investments(9K)(470K)(9.35M)0(13.59M)
Sales of Investments0218K741K0480.27K
Other Investing Activities(4M)(8.57M)(1.62M)16.4M68.2K
Investing Cash Flow(6.23M)(12.03M)(10.5M)15.76M(13.18M)
Debt Repayment19.13M(9.71M)15.24M37.49M(56.31M)
Common Stock Issued69.68M46.37M353.39M434K588.84M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(6.13M)(4.45M)(28.06M)(9.71M)(586.89K)
Financing Cash Flow82.68M32.21M340.57M28.21M531.94M
Effect of Forex Changes00(5.07M)2.38M26.29M
Net Change in Cash31.4M(33.75M)224.99M(107.72M)389.36M
Free Cash Flow(45.1M)(54.26M)(100.28M)(154.72M)(155.83M)

Abivax S.A.

NASDAQ:ABVX

Intrinsic Alpha fair value

Locked

Current Price

$83.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.